Thursday, November 21, 2024

Tevogen AI Partners with Microsoft to Speed Drug Development

Related stories

The Rise of Cloud-Native AI: Benefits, Trends, and Use Cases

Artificial Intelligence (AI) is no longer just a futuristic...

Cresta Raises $125M to Boost Human-Centric AI in Centers

The latest funding will help Cresta double down on...

Domino Integrates Tech to Scale and Govern AI for Enterprises

New Fall Release and integrations provide more options for...

Thoughtful AI Transforms Healthcare RCM with AI Agents

Thoughtful AI, an AI-powered revenue cycle transformation company, announced...

Qubrid AI Integrates NVIDIA NIM into Cloud & On-Prem

The Qubrid AI platform offers developers a simplified no-code...
spot_imgspot_img

Tevogen Bio, a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft’s extensive ecosystem. The partnership is set to accelerate and streamline the development of Tevogen’s proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations.

Mittul Mehta, CIO and Head of Tevogen AI commented “The leadership at Tevogen Bio is extremely optimistic about the future for Tevogen as a partner with Microsoft. Joining Microsoft for Startups underscores Microsoft’s conviction in Tevogen’s ability to not only innovate, but also deliver.” The partnership with Microsoft, the leading innovator in the AI space, is a substantial investment in Tevogen’s goal to provide affordable and accessible therapies. By leveraging Microsoft’s cutting-edge AI technology, Tevogen aims to push the boundaries of what AI can achieve in the biotech industry.

Also Read: Bioptimus and Proscia Join Forces to Enhance AI in Drug Development

According to The McKinsey Global Institute, Generative AI could generate $60 billion to $110 billion annually in economic value for the pharmaceutical and medtech companies, with $18 billion to $30 billion of that value attributed to commercial functions alone. Mr. Mehta, a Microsoft alum, added “The metrics are astounding, and we are excited to contribute to that economic value.”

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Source: GlobeNewsWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img